CYNTHIA RICE c Senior Vice President, Advocacy & Policy JDRF - PowerPoint PPT Presentation

CYNTHIA RICE c Senior Vice President, Advocacy & Policy JDRF

JDRF ADVOCACY UPDATE Presented by: Cynthia Rice, SVP, Advocacy & Policy, JDRF - crice@jdrf.org March 5, 2016

JDRF’S MISSION JDRF’s Vision and Mission A world without type 1 VIS ISION diabetes Accelerating life- changing breakthroughs MIS ISSION to cure, prevent and treat type 1 diabetes and its complications 3

ADVOCACY JDRF Advances Life-Changing Breakthroughs Through both Research and Advocacy  JDRF invested nearly $2 billion in research since 1970  Leverages resources from governments, other foundations  Influences policy and commercial landscape to accelerate therapies 4

ADVOCACY JDRF’s Volunteers: A Force on Capitol Hill

ADVOCACY JDRF Success: Nearly $2.5 Billion T1D Research Funding through Special Diabetes Program 150 150 150 150 150 150 150 150 150 150 150 150 150 150 70 70 100 30 30 30 30 30 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Public Law 105-33 Public Law 106-554 Public law 107-360 Public Law 110-173 Public Law 110-275 Public Law 111-309 Public Law 112-240 Public Law 113-932 Public Law 114-10 6

ADVOCACY JDRF Priority: Regulatory Pathways  Decide what clinical research can be REGULATORY AGENCIES carried out  Approve new therapies for people with T1D  Inform decisions, policies that affect T1D JDRF IMPACT  Help shape regulatory pathways  Address knowledge gaps  Safe and effective new therapies OUTCOME available to people with T1D in reasonable time period 7

ADVOCACY JDRF Success: Artificial Pancreas FDA Pathway • JDRF led process to define FDA pathway for artificial pancreas studies and product review • Final guidance issued which reflected JDRF goals and clinical recommendations • As results, new systems and components have been approved and are in development 8

ADVOCACY JDRF Priority: Health Policy  Decide what therapies are covered and at PAYERS what cost to the individual  Inform decisions and policies that affect T1D  Help shape reimbursement landscape JDRF ROLE  Address knowledge gaps  Timely access to safe, effective, and OUTCOME affordable new therapies for people with T1D 9

ADVOCACY JDRF Success: CGM Campaign Achieved Clinical Guidelines and Health Plan Coverage “ The most important milestone towards getting broad reimbursement for CGM is the …randomized, 450 -patient CGM trial by the Juvenile Diabetes Research Foundation.” JDRF Funded Trial Major Diabetes Majority of Private to Demonstrate Clinical Guidelines Health Plans Cover CGM Effectiveness Include CGM CGM for T1D 10

ADVOCACY Action Needed HEALTH POLICY  “Medicare CGM Access Act of 2015”  CGM Medicare coverage + pathway for artificial pancreas systems  S. 804 & H.R. 1427  As your members of Congress to co- sponsor at www.jdrf.org/cgm  Sign up to be an advocate!  Text “Act” to 53731 or  Visit booth in lobby or  Continuous glucose monitors  Go to www.jdrf.org/advocacy  Recommended by clinical guidelines  Tell us who you know  Covered by nearly all private plans  Congress  Medicare lags behind  FDA/CMS/health plans 11